Device performances and complications during hepatic arterial chemotherapy

G. Mondini, F. DeCian, N. Balletto, C. Spirito, R. Pellicci, M. Cosimelli, V. Quagliuolo, P. P. Cagol, D. Civalleri

Research output: Contribution to journalArticle

Abstract

The performances of totally implantable arterial infusion systems were compared in 135 patients with colorectal metastases undergoing intraarterial treatment. Seventy-eight patients received Fudr continuous infusion using either totally implantable pumps (group a = 44 pts) or ports fed by external portable pumps (group b = 34 pts) and 57 patients received bolus infusion of cisplatin (group c). Devices were cared for patency even after interruption of treatment, that was most commonly caused by disease progression. Pocket problems most frequently occurred in group a (30%) compared to groups b (9%) and c (7%) whereas a higher incidence of catheter and infusion related problems was observed in group b (109%) compared to groups a (27%) and c (32%). System failure was recorded as a cause of interruption of treatment in two, 9, and 6 cases in groups a to c, respectively. The 12-months device duration was 92% in group a, 24% in group b (median 9 months), and 65% in group c (median 17 months). Though implantable ports allow adequate infusion periods in most occasions they appear especially adequate for bolus infusions.

Original languageEnglish
Pages (from-to)168-172
Number of pages5
JournalRegional Cancer Treatment
Volume8
Issue number3-4
Publication statusPublished - 1995

Keywords

  • Implantable
  • Infusion pumps
  • Infusions intra-arterial
  • Liver neoplasms

ASJC Scopus subject areas

  • Oncology
  • Pharmacology

Fingerprint Dive into the research topics of 'Device performances and complications during hepatic arterial chemotherapy'. Together they form a unique fingerprint.

  • Cite this

    Mondini, G., DeCian, F., Balletto, N., Spirito, C., Pellicci, R., Cosimelli, M., Quagliuolo, V., Cagol, P. P., & Civalleri, D. (1995). Device performances and complications during hepatic arterial chemotherapy. Regional Cancer Treatment, 8(3-4), 168-172.